SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

GE Vernova is facing market volatility as investors weigh the company's massive record backlog and raised full-year guidance against concerns about potential tariff impacts and near-term execution hurdles in the wind segment. Despite the recent price pullback, the community remains heavily focused on the stock's fundamental role in solving the critical power and grid capacity bottlenecks currently fueling the AI data center expansion.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is at the center of intense debate following a high-profile Starship test flight, with bullish sentiment focused on the successful deployment of next-generation Starlink satellites and advancements in reusable rocket technology. Meanwhile, bearish investors remain skeptical of the stock's valuation and potential sell-off pressure as insider lock-up expirations approach.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is seeing increased investor attention as the company advances its Hydrochemolytic Technology, highlighted by positive pilot plant results and a recent uplisting to the Toronto Stock Exchange. The community is actively discussing the stock's potential for commercial scaling and its strategic expansion into paraffinic crude upgrading, while some participants remain focused on the firm's path to achieving long-term profitability.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as it faces a legal challenge from 12 U.S. states seeking to block its $111 billion merger with Warner Bros. Discovery on antitrust grounds. While the company maintains that the deal is pro-competitive and highlights international regulatory approvals, investors are closely monitoring the impact of potential litigation delays, ticking fees, and regulatory hurdles.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending as investors debate the impact of its $1.5 billion acquisition of Personalis, which seeks to bolster its position in the competitive oncology and minimal residual disease (MRD) markets. While the community is dividedwith some bulls pointing to long-term data advantages and institutional backing as a strong entry opportunity, while bears cite dilution concerns and intense short interestmany are closely watching how the stock manages near-term price volatility following this major strategic deal.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is surging as investors react to a planned BLA resubmission for RP1 in advanced melanoma, fueled by reports of newfound regulatory flexibility following a recent FDA leadership shakeup. The community is actively debating the durability of the company's clinical data and the sustainability of the current rally given the stock's previous regulatory setbacks and ongoing funding requirements.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is gaining significant community attention as investors track the upcoming rollout of its second-generation driverless trucks and anticipate key purchase order announcements. Discussion is heavily focused on the company's long-term scaling potential, internal hardware progress, and its ability to maintain execution timelines despite broader market headwinds.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is currently trending as shareholders and analysts dissect the company's prospects following recent regulatory developments and institutional portfolio adjustments. The community is actively debating the potential impact of pending immunotherapy reimbursement on valuation, while weighing concerns over cash runway and competitive pressures in the MRD diagnostics space.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors react to Michael Burry increasing his long position, which has sparked a heated debate regarding the company's growth prospects and competitive landscape against emerging prediction markets. The community is deeply divided between long-term bulls highlighting institutional accumulation and strong sports betting engagement, and vocal skeptics focused on valuation concerns, regulatory risks, and the stock's lack of upward momentum.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

The ARK Innovation ETF is facing intense community scrutiny as investors debate its long-term performance and the high-conviction, often contrarian, trading strategy led by Cathie Wood. Discussions frequently highlight the fund's significant underperformance compared to broader market indices like the QQQ and S&P 500, fueling polarized debates over the viability of her growth-focused investment thesis.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

Gossamer Bio, Inc. (NASDAQ: GOSS) (the Company or Gossamer), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today...

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (Gossamer or the Company) (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has...

GOSS Investors Have Opportunity to LeadGossamer Bio, Inc.Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (Gossamer or the Company) (NASDAQ: GOSS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the...

GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) Investors to Today's Lead Plaintiff Deadline in Securities Class Action

GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) Investors to Today's Lead Plaintiff Deadline in Securities Class Action GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) Investors to Today's Lead Plaintiff Deadline in Securities Class Action PR Newswire SAN FRANCISCO, June...

GOSS 2-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS

GOSS 2-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS GOSS 2-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk...

Deadline Soon: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming June 1, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Gossamer Bio, Inc. (Gossamer or the Company) (NASDAQ: GOSS) securities between June 16...

GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026

GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 PR Newswire NEW YORK, May 29...

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.

Gossamer Bio Inc

Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash?

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.11	--	--	N/A
Q1 '26	-$0.17	-$0.20	-20.85%	MISSED
Q4 '25	-$0.20	-$0.21	-7.33%	MISSED
Q3 '25	-$0.19	-$0.21	-9.80%	MISSED
Q2 '25	-$0.18	-$0.17	4.03%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

GOSSGossamer Bio Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest GOSS News